GLYZIA 100MG TABLET

GLYZIA 100MG TABLET contains Sitagliptin as its active ingredient. Sitagliptin is a medication classified as a dipeptidyl peptidase-4 (DPP-4) inhibitor. It is used for the management of type 2 diabetes mellitus to help control blood sugar levels.

Mechanism of Action:

Sitagliptin works by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4), which inactivates incretin hormones. By inhibiting DPP-4, Sitagliptin increases the levels of active incretin hormones in the body. These hormones stimulate the release of insulin from the pancreas and decrease the production of glucagon, thereby reducing blood sugar levels.

Uses:

GLYZIA 100MG TABLET is prescribed for the treatment of type 2 diabetes mellitus in adults. It is used as an adjunct to diet and exercise to improve glycemic control. By lowering blood sugar levels, Sitagliptin helps reduce the risk of complications associated with diabetes, such as cardiovascular disease, kidney damage, and nerve damage.

Administration:

GLYZIA 100MG TABLET is taken orally, usually once daily, with or without food. The dosage may vary depending on individual patient factors, including kidney function and response to treatment. It is important to adhere to the prescribed dosage regimen and maintain regular monitoring of blood glucose levels.

Side Effects:

Common side effects of GLYZIA 100MG TABLET may include:

• Upper respiratory tract infection
• Headache
• Nausea
• Stomach upset
• Diarrhea
• Hypoglycemia (low blood sugar) when used with other antidiabetic medications
• Hypersensitivity reactions (rash, itching)

Precautions:

Before using GLYZIA 100MG TABLET, patients should inform their healthcare provider about any pre-existing medical conditions, allergies, or medications they are currently taking. It is important to monitor kidney function regularly, as Sitagliptin is primarily eliminated through the kidneys. GLYZIA should be used with caution in patients with a history of pancreatitis or those at risk of heart failure.

Contraindications:

GLYZIA 100MG TABLET is contraindicated in patients with a known hypersensitivity to Sitagliptin or any other components of the tablet. It should not be used in patients with type 1 diabetes mellitus or diabetic ketoacidosis. GLYZIA should be discontinued temporarily before any procedure involving intravenous contrast media and restarted only after renal function is confirmed to be normal.

Conclusion:

GLYZIA 100MG TABLET, containing Sitagliptin, is an effective medication used for the management of type 2 diabetes mellitus. It helps improve glycemic control by lowering blood sugar levels through its mechanism of action on incretin hormones. Patients should use this medication as directed by their healthcare provider and be aware of potential side effects.